Autumn 2025
CDMOs & CROs
The Trump administration’s trade policy has hit CDMOs and CROs hard. Trade barriers against Chinese service providers and raw material suppliers have increased biologics production costs and caused supply shortages. Small biotech firms dependent on these contractors are particularly affected.
In this Special:
- Strategic Value of Isolator Lines in Manufacturing
- Data-driven excellence: the cornerstone of clinical research
- CDMO: An SAP S/4HANA transformation in <10 months
- Biomanufacturing in Switzerland
- AGC Biologics Team Fuels Shigella Vaccine Trials
- Ultra low freezer for intensive use
- Interview with Samanta Cimitan, CEO, Celonic
- Antibodies: Cornerstone of ADC Precision and Efficacy
